Blog

Fadi Haddad: Happy to present data on the role of inotuzumab in patients with B-ALL at ASH24

Fadi Haddad/X

Dec 12, 2024, 14:22

Fadi Haddad: Happy to present data on the role of inotuzumab in patients with B-ALL at ASH24

Fadi Haddad, Assistant Professor in the Department of Leukemia at the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Happy to present data from MD Anderson Cancer Center on the role of inotuzumab in eradicating MRD in patients with B-ALL at ASH24:-

N=30
67% response rate, MRD conversion
3-year OS 56%
Low grade AEs, but 2 SOS (both in patients with ponatinib, Gr 5=1).”

Fadi Haddad is an Assistant Professor in the Department of Leukemia at the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, TX. He serves as a member of the Leading Clinical Research Faculty Learning Series. His postgraduate training includes a clinical fellowship in leukemia at MD Anderson Cancer Center and a clinical residency in hematology/oncology at Hotel Dieu de France Hospital in Beirut.

ASH24 cancer Cancer Medicine Fadi Haddad fight against cancer Global fight against cancer Happy Inotuzumab Leukemia MD Anderson Cancer Center MRD OncoDaily Oncology University of Texas

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Giuliana Rancic and Breast Cancer: How She Went Against, How She Survived, and More

Vincent Rajkumar: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma

"The Doctor Who Always Has Candies in His Pocket": A Conversation with Professor Guangchao Zhang, Pioneer of Pediatric Surgical Oncology in China

Wanda Sykes and Breast Cancer: How She Went Against, How She Survived, and More

Special Coverage